University of Melbourne and SMART Technologies partner in groundbreaking global research on technology supports for neurodivergent learners

By on    Internet, Picture Gallery  

University of Melbourne and SMART Technologies partner in groundbreaking global research on technology supports for neurodivergent learners

SMART Technologies and the University of Melbourne s collaborative research promise impactful ways to engage neurodivergent students.

SMART Technologies, a global leader in interactive education technology, has partnered with the University of Melbourne to launch the first-of-its-kind research initiative exploring how classroom environments can better support neurodivergent learners. The study identified key strategies and tools that promote engagement, reduce barriers, and empower these studen

Infosys: Strong growth of 6.1% YoY in CC, 80 bps YoY operating margin expansion

By on    Internet, Software  

– Large deal TCV of $2.5 billion including 63% net new; Headcount increased by 5,591
– FY25 revenue guidance revised to 4.5%-5.0%

Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, delivered strong and broad-based performance with $4,939 million in Q3 revenues, growth of 1.7% sequentially and 6.1% year on year in constant currency. Operating margin for Q3 was at 21.3%, increase of 0.2% sequentially. Free cash flow for Q3 was high

Infosys and Tennis Australia Create New Generative AI Innovations at the Australian Open 2025

By on    Internet, Software  

Launch of Beyond Tennis : A new generative AI tennis league with AI players and data-driven tournaments

Infosys (https://www.infosys.com/) (NSE: INFY), (BSE: INFY), (NYSE: INFY), a global leader in next-generation digital services and consulting, in partnership with Tennis Australia (https://apc01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.tennis.com.au%2F&data=05%7C02%7CShruti.Pai%40infosys.com%7Ce74a953ce42e4341f62a08dd33a3fc68%7C63ce7d592f3e42cda8ccbe764cff5eb6%7C0%7C0%7C63

BAIBYS™ Announces a Breakthrough in Fertility Treatment with a Newly CE Marked IVF System

By on    Internet  

The Autonomous Sperm Selection AI-based Robotic System is Poised to Transform the IVF Market

BAIBYS™ (https://www.baibys.com/), a pioneering Israeli startup in AI-powered micro-robotics for Artificial Reproductive Technology (ART), today announced it has received the CE mark for its innovative BAIBYS™ system (https://www.youtube.com/watch?v=Vaa_HlxuAm0). This milestone enables the company to commercialize its autonomous sperm selection technology across Europe, marking a significant

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

By on    Internet, Picture Gallery  

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Back to media releases (https://norgine.com/media)

Next media release (https://norgine.com/press_release/norgine-receives-positive-chmp-opinion-recommending-approval-of-npj5008-dantrolene-sodium-hemiheptahydrate-for-the-treatment-of-malignant-hyperthermia/)

Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, i

Counter Drone Technology Leader Sentrycs Announces its latest Public Safety Deals including new customers in North America

By on    Internet  

Sentrycs Concludes a Year of Record Growth with its C-UAS Technology Capable of Addressing the Growing Drone Threat Across Four Continents

Sentrycs, a technology leader in the Counter-Unmanned Aerial Systems (C-UAS) industry, announced today its continued progress globally within the public safety market. The company recently closed agreements with two new law enforcement organizations, including one in North America. These new agreements will deliver core protocol manipulation sensor solutions

Infosys Achieves Binding Corporate Rules Certification from EU Data Protection Authorities

By on    Internet, Software  

– First India-headquartered company to receive BCR certification
– An accredited data privacy compliance framework for international data transfers from the EU

Infosys (https://www.infosys.com/) (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced that it has obtained regulatory approvals for its Binding Corporate Rules (BCR) from the Hesse Data Protection Authority, Germany, following concurrence from the EDPB (European Data

Infosys Strengthens Strategic Collaboration with Google Cloud to Boost Enterprise AI Innovation, Establishes Center of Excellence

By on    Internet  

Leveraging Infosys Topaz and Google Cloud technology, the center of excellence will foster co-innovation to deliver transformative AI-powered solutions

Infosys (https://www.infosys.com/) (NSE: INFY), (BSE: INFY), (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced the launch of a Google Cloud center of excellence, powered by Infosys Topaz (https://www.infosys.com/services/data-ai-topaz.html), to foster enterprise AI innovation. The center will serve

Good overall result and revenue growth for the ZEISS Group

By on    Internet, Picture Gallery  

Good overall result and revenue growth for the ZEISS Group

ZEISS Group revenue increased to just under 11 billion euros (10.894 billion euros), (up 8% on the prior year) – EBIT 1,444 million euros (prior year: 1,686 million euros, EBIT margin 13%). Mixed development in the segments. High spend on research and development equivalent to 15% of revenue, more than 46,000 employees worldwide.

– Increasingly challenging market environment for the direct-to-market segments
– Strong growth in the Semiconductor Manufacturing Technology segment
– Ou

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

By on    Internet, Picture Gallery  

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

– Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases.
– The EC approval follows a positive opinion issued on 19 October 2024 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and is applicable to all 27 European Union (EU) Member States plus Iceland, Norway and Liechtenst

1 2 3 4 5 … 10